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Abstract
Background: Intracranial arachnoid cysts (AC) are membranous sacs filled with CSF-like fluid that are commonly
found in the temporal fossa. The majority of ACs are congenital. Typical symptoms are headache, dizziness, and
dyscognition. Little is known about genes that contribute to the formation of the cyst membranes.
Methods: In order to identify differences in gene expression between normal arachnoid membrane (AM) and cyst
membrane, we have performed a high-resolution mRNA microarray analysis. In addition we have screened DNA
from AC samples for chromosomal duplications or deletions using DNA microarray-based copy number variation
analysis.
Results: The transcriptome consisting of 33096 gene probes showed a near-complete similarity in expression
between AC and AM samples. Only nine genes differed in expression between the two tissues: ASGR1, DPEP2,
SOX9, SHROOM3, A2BP1, ATP10D, TRIML1, NMU were down regulated, whereas BEND5 was up regulated in the AC
samples. Three of the AC samples had unreported human DNA copy number variations, all DNA gains.
Conclusions: Extending results of previous anatomical studies, the present study has identified a small subset of
differentially expressed genes and DNA alterations in arachnoid cysts compared to normal arachnoid membrane.
Background
Arachnoid cysts (AC) are relatively common benign
lesions, reported to be found in 1.1% of the adult popu-
lation [1]. Typical symptoms in adults are headache, diz-
ziness, seizures [2] and dyscognition [3]. Although ACs
can be found throughout the central nervous system
(CNS), they show a marked predilection for the tem-
poral fossa (figure 1) [2,4-6]. In the majority of cases,
skull indentations and a large corresponding temporal
fossa, as seen on MRI or CT, suggest that ACs arise
before the neurocranium is fully developed. Anatomi-
cally, ACs are formed by a splitting of the arachnoid
mater (AM) [7-9]. The size of ACs is classified accord-
ing to three Galassi types [10]. Briefly, a type I cyst is
small, biconvex, and located at the anterior temporal
pole. A type II cyst involves the proximal and intermedi-
ate segments of the Sylvian fissure, and a type III cyst
involves the entire Sylvian fissure, and has often a
marked radiological mass effect.
The cyst wall is composed of non-neoplastic ara-
chnoid cells, and it has been suggested that these cells
could secrete cerebrospinal fluid (CSF) [11,12]. The cyst
fluid has a chemical composition similar to that of CSF
[13-15]. Thus, the frequently seen stable size of ACs
might represent a steady state where fluid influx equals
the efflux. However, until a proteomic profiling compar-
ing CSF and AC fluid is performed, it remains question-
able how similar these fluids are.
Given the likely congenital nature of ACs, it is possi-
ble that altered gene expression in neural crest cells at
the time of leptomeningeal development may contri-
bute to cyst formation. However, so far there has been
very little research on the molecular biology of AC.
Hence, putative candidate genes with a role in AC for-
mation are yet to be found. Several methods are avail-
able for studying gene expression. As mRNA
microarray has the advantage that it can be used to
analyze a large number of genes simultaneously, it has
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jects of the transcriptome.
Previously, we have characterized the molecular signa-
ture of intracranial meningiomas [16]. As these tumors
derive from arachnoid cap cells, and normal arachnoid
in sufficient quantities is difficult to obtain, we used
samples from arachnoid cysts as control tissue. There-
fore, it would be interesting to determine whether the
gene expression signature of normal arachnoid mem-
brane differs from that of AC membranes. If these sig-
natures were similar, it would imply that AC tissue
could be used as a justified source of control tissue in
molecular biological studies of conditions involving the
arachnoid, such as subarachnoid haemorrhage, menin-
giomas, and meningitis.
I nt h ec u r r e n ts t u d yw eh a v ep e r f o r m e dam o l e c u l a r
characterization of temporal fossa AC membranes. The
aims were: 1) to determine the general gene expression
profile of AC samples compared with that of normal
AM tissue. In this way we aimed at finding candidate
genes with a role in AC development; 2) to search for
DNA regions with altered copy number variations
(CNV) in AC tissue. The study showed marked similari-
ties in the gene expression profiles of the AC and AM
samples; however, we identified a small subset of differ-
entially expressed genes and DNA alterations in ara-
chnoid cysts compared to normal tissue.
Methods
Patients and tissue sampling
Tissue from sporadic, non-familial ACs, as well as normal
arachnoid, was harvested during surgery and stored in
liquid N2 in the Bergen neurosurgical tissue bank at the
Department of Neurosurgery, Haukeland University Hos-
pital, until analysis. A parallel sample was taken for histo-
logical verification of the diagnosis. We obtained written
consent from the patients for the study, which was
approved by the Regional Ethical Committee. A total of
11 temporal AC were included in the study (table 1), and
we used samples from the arachnoid membrane (cisterna
magna) of four adult patients as control tissue. These
patients were all undergoing posterior fossa surgery for a
solitary cerebellar tumour without radiological or intrao-
perative signs of extension to the cerebellar surface and
removal of the arachnoid was part of the surgical proce-
dure. Three of these patients had metastases from adeno-
carcinoma and one had a hemangioblastoma (not von
Hippel-Lindau type). None of the patients had any signs
of tumour cell dissemination to the arachnoid, and there
was no history or MRI sign of previous haemorrhage in
the patient with hemangioblastoma. Because of the very
limited amounts of tissue available for analysis, not all
the cysts and normal AM were studied with all the tech-
niques; details are given under each method section
below (see also table 1).
RNA extraction and microarray
Seven AC and two controls were studied with mRNA
microarray. The details of RNA extraction and microar-
ray analysis have previously been reported [16]. Briefly,
we used the Qiagen RNeasy minikit (QIAGEN GmbH,
Hilden, Germany) to extract total RNA. After RNA
quality and quantity assessment, we then constructed
cDNA with RT-PCR reagents (Applied Biosystems, Fos-
ter City, USA). Gene expression microarray analysis was
performed on the ABI 1700 Expression Array System
(Applied Biosystems) using the Applied Biosystems
Chemo luminescent RT-IVT Labeling Kit and Human
Genome Survey Microarray V1.0.
Analysis of microarray data
Signal intensities generated with the ABI 1700 Expres-
sion Array System were imported into the J-Express Pro
2.7 software (MolMine AS, Bergen, Norway) [17], where
inter-array quantile normalization was performed to
minimize the effect of external variables on the data. All
control spots and flagged spots were removed, leaving
33096 gene probes available for analysis. First, we per-
formed an unsupervised hierarchical cluster analysis in
which the group belonging to the samples was defined.
Second, we used Significance Analysis of Microarrays
Figure 1 Radiological presentation of an arachnoid cyst (AC).
Computed tomography (CT) scan of a large, left-sided temporal AC.
Note the splitting of the Sylvian fissure and the compression of the
frontal and temporal lobes, all classical features of a Galassi type 3
cyst [10]. The midline is displaced 6 mm to the right. Note the
enlargement of the left cranial vault suggesting that the AC was
present before the neurocranium was fully developed.
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and AM samples [18] and generate gene lists of differ-
entially expressed genes between these groups. With
SAM, the false discovery rate (FDR) of the gene lists
was calculated. FDR returned the number of false posi-
tive genes present on the gene list. A measure of FDR is
the Q value, which conveniently shows an estimation of
t h eF D Ri np e r c e n t .I nt h ec u r r e n ts t u d yo n l yg e n e s
with a Q value <1.0% were accepted as being differen-
tially expressed. The microarray files are deposited at
the NCBI Gene Ontology Omnibus (http://www.ncbi.
nlm.nih.gov/geo; GEO accession # GSE19727).
Quantitative reverse transcriptase real-time polymerase
chain reaction (qRT-PCR)
Eleven AC and four AM samples were analyzed with
qRT-PCR [16,19]. Briefly, gene specific primers and
MGB-probes were obtained from Applied Biosystems
AssayOnDemand (AOD). Quantification of specific
mRNA was performed using the ABI 7900 instrument
(Applied Biosystems). b-actin probes were used for
endogenous normalization control to adjust for unequal
amounts of RNA. Statistical comparisons were per-
formed using the Mann-Whitney rank sum test with the
GraphPad Prism™ v.4.0 software (GraphPad Software,
Inc. La Jolla, USA). P-values were two-sided and consid-
ered significant when <0.05.
DNA purification and copy number variation (CNV)
analysis
Six AC samples (AC5056, AC6004, AC6049, AC6051,
AC8005, and AC8010) were included in the CNV analy-
sis, which was performed using the Affymetrix Genome-
Wide Human SNP array 6.0 (Affymetrix, Santa Clara,
USA). DNA used in the CNV experiment was purified
from the tissue used for RNA purification and 350 μlo f
the flow through fraction from the RNEasy column was
mixed with 1 μl acrylamide (5 ng/μl) and 500 μl ethanol.
The precipitated DNA was collected by centrifugation at
14000 g for 10 min. The precipitated DNA was dis-
solved in 2 ml G2 buffer (Qiagen) and purified using
the Qiagen DNA mini kit (cat. no. 51304). Next, 250 ng
dsDNA was restricted in each of two separate reactions
with NspI and StyI. NspI and StyI adaptors were then
ligated to the DNA fragments with T4 DNA ligase
before PCR. After PCR, 3 μlo fb o t hN s p Ia n dS t y Ip r o -
ducts were run on a 2% agarose gel. A smear between
200 and 1100bp was found. The PCR products were
cleaned and the DNA concentration measured with
NanoDrop (Thermo Scientific, USA). Thereafter, puri-
fied PCR products were fragmented and hybridized to
the Affymetrix 6.0 chip. The chips were scanned and
data processed accordingly with the Genotyping Con-
sole. CNVs were crosschecked with The Database of
Genomic Variation (http://projects.tcag.ca/variation/
[20]).
Results
RNA Microarray analysis
The unsupervised hierarchical cluster analysis did not
detect any subgroups of the AC samples based on the
g e n e r a lg e n ee x p r e s s i o n .W i t hS A Mt h eg e n el i s t s
derived with 400 and 1000 permutations returned iden-
tical results. The top 100 genes calculated with SAM
had a Q value of 10.4 (see additional file 1: Top 100
candidate genes derived from Significance Analysis of
Table 1 Demographic data and techniques used on membrane tissue from 11 arachnoid cyst (AC) patients and 4
arachnoid membrane (AM) patients.
Case # ID Gender Age Galassi type Side Method of investigation
1 AC_2005-056 Male 52 3 Left mRNA microarray, qRT-PCR, CNV
2 AC_2006-004 Female 34 2 Left mRNA microarray, qRT-PCR, CNV
3 AC_2006-049 Male 50 3 Right mRNA microarray, qRT-PCR, CNV
4 AC_2006-051 Female 35 2 Right mRNA microarray, qRT-PCR, CNV
5 AC_2006-058 Female 33 2 Right mRNA microarray, qRT-PCR
6 AC_2008-005 Female 27 2 Left mRNA microarray, qRT-PCR, CNV
7 AC_2008-010 Male 44 2 Left mRNA microarray, qRT-PCR, CNV
8 AC_39 Male 51 1 Right qRT-PCR
9 AC_2003_031 Male 54 2 Left qRT-PCR
10 AC_2004_060 Female 64 3 Left qRT-PCR
11 AC_2008-004 Male 9 2 Left qRT-PCR
12 AM_2006-048 Female 82 n.a. n.a. mRNA microarray, qRT-PCR
13 AM_2008-008 Male 49 n.a. n.a. mRNA microarray, qRT-PCR
14 AM_2006-044 Female 43 n.a. n.a. qRT-PCR
15 AM_2006-057 Female 53 n.a. n.a. qRT-PCR
qRT-PCR: quantitative reverse transcriptase real-time polymerase chain reaction, CNV: DNA copy number variation analysis, n.a: not applicable.
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arachnoid membrane samples). We found nine genes
matching a Q value <1 (table 2). All these genes had
fold change differences ≥ +/- 2.6. As seen by the average
expression signals, all these genes had signal intensities
either for AC, AM, or both above the anticipated back-
ground noise (>1000).
Quantitative RT-PCR
The following genes differentially expressed in the SAM
analysis were also analyzed with qRT-PCR to validate
the microarray results: ATP10D, BEND5, SHROOM3,
SOX9. For all the studied genes except SOX9 (p = 0.09),
the difference in expression profile between AC and ara-
chnoid membranes was statistically significant (ATP10D:
p =0 . 0 0 5 ,BEND5: p =0 . 0 0 7 ,SHROOM3: p =0 . 0 0 5 ,
figure 2). We also investigated the correlation between
qRT-PCR and microarray analyses for the expression of
these three genes, and found a significant correlation for
all three (r
2 =0 . 8 ,p = 0.0003; r
2 =0 . 5 ,p =0 . 0 2 ;r
2 =
0.8, p = 0.0002, respectively, figure 3).
DNA copy number variation (CNV) analysis
In DNA purified from AC samples we found several
CNVs already registered in the Database of Genomic
Variants. However, for three of the samples
(AC_2006_051, AC_2005_056, AC_2006_004) we
found 14 CNVs with no current reports in the database
(table 3). All CNVs in our samples were chromosomal
gains. The unreported CNVs were also cross checked
against a population of 361 Norwegians with no history
of AC, whose genome had been examined for the pre-
sence of CNVs with the same platform used in our
experiment. None of the 14 AC CNVs were found in
these control samples.
Discussion
We studied the global gene expression signature of tem-
poral fossa AC and normal arachnoid membranes with
the aim of detecting differently expressed genes. The
main finding, however, was a near-complete similarity,
by unsupervised cluster analysis and SAM of 33096 indi-
vidual gene probes. Nevertheless, using SAM we found
nine genes with differential expression between AC and
AM samples. These nine genes (ASGR1, DPEP2, SOX9,
SHROOM3, A2BP1, ATP10D, TRIML1, BEND5, NMU)
are novel candidate genes that might be associated with
the pathogenesis of temporal fossa ACs.
In mice it has been shown that mutations in the
SHROOM3 gene result in exencephaly, acrania, facial
clefting, and spina bifida; all presumably due to failed
closure of the neural tube [21]. The authors suggested
that SHROOM3 is involved in the regulation of
cytoarchitecture that is required for proper neurulation.
Another study, has found expression of SHROOM3 in
several human tissues including the brain [22]. The uni-
form down-regulation of SHROOM3 in the AC samples
is an interesting finding that indicates that specific inac-
tivation of SHROOM3 in foci of arachnoid cells may
contribute to the development of cysts.
SOX9 is a transcription factor located at chromosome
17q24, and inactivation of one allele causes campomelic
dysplasia (CD) [23]. CD patients typically have short,
bowed long bones, craniofacial defects and female to
male sex reversal. Interestingly, cystic hygroma and cys-
tic kidneys have been reported in CD [24]. In the devel-
oping brain it is expressed in neural crest cells; the very
same cells that differentiate into meninges, and animal
studies have shown that inactivation of SOX9 in these
cells results in craniofacial maldevelopment [25].
From the literature, none of the remaining differen-
tially expressed genes are reported to have known func-
tions linking them to cystogenesis or neural tube
development. However, this does not imply that the
genes have no function in AC formation as the biologi-
cal function of many genes are poorly characterized and
many genes may have different or multiple functions in
different tissues at different stages during the life cycle.
Table 2 Differentially expressed genes separating arachnoid cysts (AC) from normal arachnoid membranes (AM)
determined by microarray analysis.
ABI 1700 Probe ID Gene symbol Gene name Average signal AC Average signal AM Fold change Q value
220229 ASGR1 asialoglycoprotein receptor 1 233 2009 -8.6 0
166918 DPEP2 dipeptidase 2 378 2571 -6.8 0
201106 SOX9 SRY (sex determining region Y)-box 9 871 9030 -10.4 0
207317 SHROOM3 shroom family member 3 222 3188 -14.4 0
167968 A2BP1 ataxin 2-binding protein 1 220 1197 -5.4 0
137724 ATP10D ATPase, Class V, type 10D 30740 88307 -2.9 0
158289 TRIML1 Tripartite motif family-like 1 296 1040 -3.5 0
130750 BEND5 BEN domain containing 5 10888 4270 2.6 0
102108 NMU neuromedin U 228 1537 -6.7 0
Key: Average signal intensities for the AC and AM groups are shown in column 4 and 5. Differentially expressed genes were identified by Significance Analysis of
Microarrays (SAM) using 400 permutations. The Q value (%) represents the number of false positive candidate genes in the gene list derived from SAM.
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PCR. Plots showing the expression of three genes analyzed by
quantitative reverse transcriptase real-time polymerase chain
reaction (qRT-PCR) for arachnoid cyst tissue (AC, n = 11) and control
arachnoid tissue (AM, n = 4) for three genes: A) ATP10D, B) BEND5,
and C) SHROOM3. The expression of all three genes was
significantly different between the two tissues.
Figure 3 Correlation analysis between microarray signal and
quantitative reverse transcriptase real-time polymerase chain
reaction (qRT-PCR). Plots showing the correlation between the
microarray signal and the expression profile from qRT-PCR analyses
for three differentially expressed genes separating arachnoid cysts
(AC, n = 7) and arachnoid membranes (AM, n = 2): A) ATP10D, B)
BEND5, C) SHROOM3. Data were log transformed before the
Pearson correlation was calculated.
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erties of these genes in humans. Hence, based on cur-
rent but incomplete knowledge, the most promising
candidate genes with a role in the formation of ACs are
SHROOM3 and SOX9.
For validation of the differentially expressed genes,
we selected four of them for qRT-PCR: ATP10D,
BEND5, SHROOM3 which were significantly altered in
the ACs (p = 0.005, p = 0.008, p = 0.005, respectively),
and SOX9 which showed the same trend, but did not
reach significance (p = 0.08). The expression of
ATP10D, BEND5, SHROOM3 in the qRT-PCR study
correlated significantly with that of the microarray
study; i.e. a low expression found in the AC by micro-
array was similarly low by qRT-PCR. This adds internal
validity to our microarray platform and thus to the
results in general.
Microarray-based CNV analysis was used to study
chromosomal aberrations in a detailed manner; with
the platform used in our study, more than 946,000
copy number probes span the genome. Thus, submi-
croscopic DNA regions with duplications or deletions
can be identified. Such regions might contain genes of
importance for the formation of the cysts. Because of
limited amounts of tissue only six AC samples were
subjected to CNV analysis. In three of these cases we
found a total of 14 CNVs so far not reported in the
human genome: all of which were chromosomal gains
(table 3). In our samples, the CNVs were located on
c h r o m o s o m e s7 ,8 ,1 0 ,1 1 ,1 2 ,1 4 ,1 5 ,1 6 ,1 7 ,a n d1 9 ,
and several genes are known to be located in these
regions. The CNV results were matched against the
publicly available Toronto database, as well as against
a population based Norwegian sample of 361 indivi-
duals located in our laboratory. Although there were
no mutual CNVs present in all the AC samples, this
does not weaken their potential role. On the contrary,
a growing body of evidence from studies on schizo-
phrenia and autism suggests that different DNA altera-
tions on different chromosomes may ultimately
contribute to the development of the same phenotype
[26-28]. This illustrates the complexity of the genome
and its regulation in health and disease, and suggests
that similar mechanisms may underlie the pathogenesis
of AC.
Gene expression research on diseases affecting the
arachnoid membrane (e.g. meningiomas, post-SAH
inflammation and meningitis) requires normal arachnoid
tissue as control. Since normal arachnoid is more diffi-
cult to obtain than AC tissue in quantities sufficient for
gene expression analysis, one could ask whether ACs
could be used in this research as a substitute for normal
arachnoid membrane. In the current study we have
shown that the vast majority of genes had similar
expression profiles in AC and normal arachnoid mem-
branes. If adjusted for the nine differentially expressed
genes, our results suggest that AC tissue may be used as
control tissue in such studies.
A limitation of the present study is the low number
o fn o r m a lA Ms a m p l e su s e da sc o n t r o lt i s s u e .A tt i m e
of study we had only two AM samples sufficient for
cDNA microarray and four AM samples for qRT-PCR
analysis. Because of this we had to use strict criteria in
the data analysis of the microarray results for the
detection of differentially expressed genes. However,
when we validated the genes with qRT-PCR and
included additional AC and AM samples, the microar-
r a yf i n d i n g sw e r ec o n f i r m e d .A sw ea l s oh a v es h o w n ,
we found a significant correlation between the qRT-
PCR and microarray results. Furthermore, all AC
Table 3 Three arachnoid cyst (AC) samples with chromosomal gains detected with DNA copy number variation (CNV)
analysis.
Sample CNV present in sample CNV in region registered in the
Database of Genomic Variants
a
Genes known to be present in region
AC_2006-051 arr 7p22.1(6498207-6600621)x3
arr 8p11.21(42175206-42281148)x3
arr 14q23.3(64978487-65093419)x3
Inversion and deletion
No reports
Inversion
GRID2IP, C7orf26, ZDHHC4
IKBVB, PLAT
FUT8
AC_2005-056 arr 12q13.13(51746148-51886072)x3
arr 12q24.31(121446657-121547275)x3
arr 14q23.3(64978487-65105576)x3
arr 15q15.3(42468491-42598658)x3
arr 16p13.3(3431656-3522375)x3
Small gains, inversions, and loss
spanning region
No reports
Inversion
No reports
Loss
ITGB7, ZNF740, CSAD, SOAT2, IGFBP6, SPRYD3
ZCCHC8, CLIP1
FUT8
CTDSPL2, CASC4
CLUAP1, C16orf90, NAT15, ZNF597
AC_2006-004 arr 10p12.31(21822848-21949193)x3
arr 11q12.3(62557724-62669857)x3
arr 12q13.3(51724073-51844567)x3
arr 16p13.3(3522375-3631656)x3
arr 17q21.31(38560627-38814457)x3
arr 19p13.12(14246734-14391382)x3
Loss
Loss
Loss
Loss
Loss
Loss
MLLT10, C10orf140, C10orf114
SLC22A24
SOAT2, IGFBP6, CSAD, SPRYD3, TENC1
BTBD12, NLRC3, CLUAP1
NBR1, LOC100130581, TMEM106A,
DDX39, CD97,
aInformation extracted from the Database of Genomic Variants (http://projects.tcag.ca/variation/?source=hg18) as of October, 2009 [20].
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infratentorial. Thus, one might argue that the differen-
tial gene expression may rely on purely anatomical
grounds. However, it is our opinion that structurally
there is no difference between supra- and infratentorial
arachnoid, and that if this were true many more genes
would be differentially expressed.
Conclusions
In summary, this is the first study on the mRNA gene
expression in intracranial AC membranes and we have
shown that for the vast majority of genes, the expression
profiles in AC and AM samples were similar. However,
our study showed that a small subset of genes was dif-
ferentially expressed in the AC samples compared to
normal tissue. The differential expression level of these
genes might be important for the development of ACs.
We also found duplicated DNA regions. Particularly, the
functional role of the altered gene expression for
SHROOM3 and SOX9 must be further studied in model
systems and the findings of duplicated chromosomal
regions have to be verified in replication studies con-
taining more samples.
Additional file 1: Top 100 candidate genes derived from
Significance Analysis of Microarrays (SAM) comparing arachnoid
cysts (AC) and arachnoid membrane samples. The rows represent the
top 100 genes derived from Significance Analysis of Microarrays (SAM). In
the columns the signal intensities generated from the microarray analysis
are provided for each of the samples (arachnoid membranes, AM, n = 2;
arachnoid cysts, AC, n = 7). Gene identifiers, cytoband, and biological
processes according to the PANTHER database (http://www.pantherdb.
org) are provided for each gene. Where no information on gene
function or name is currently known, the term “null” is used.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1743-8454-7-6-
S1.PDF]
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